GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » Cyclically Adjusted Revenue per Share

SILO Pharma (SILO Pharma) Cyclically Adjusted Revenue per Share : $-0.06 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

SILO Pharma's adjusted revenue per share for the three months ended in Mar. 2024 was $0.006. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $-0.06 for the trailing ten years ended in Mar. 2024.

During the past 12 months, SILO Pharma's average Cyclically Adjusted Revenue Growth Rate was -200.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-20), SILO Pharma's current stock price is $2.03. SILO Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $-0.06. SILO Pharma's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SILO Pharma was 250.00. The lowest was 22.33. And the median was 91.63.


SILO Pharma Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for SILO Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SILO Pharma Cyclically Adjusted Revenue per Share Chart

SILO Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.06 0.06 0.03

SILO Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.06 0.03 -0.06

Competitive Comparison of SILO Pharma's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, SILO Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SILO Pharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where SILO Pharma's Cyclically Adjusted PS Ratio falls into.



SILO Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SILO Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.006/131.7762*131.7762
=0.006

Current CPI (Mar. 2024) = 131.7762.

SILO Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 -0.406 100.560 -0.532
201409 -0.182 100.428 -0.239
201412 0.001 99.070 0.001
201503 0.097 99.621 0.128
201506 0.092 100.684 0.120
201509 -0.410 100.392 -0.538
201512 0.078 99.792 0.103
201603 0.023 100.470 0.030
201606 -0.285 101.688 -0.369
201609 -0.337 101.861 -0.436
201612 -0.067 101.863 -0.087
201703 0.889 102.862 1.139
201706 0.002 103.349 0.003
201709 0.007 104.136 0.009
201712 -0.020 104.011 -0.025
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.085 108.420 0.103
202003 0.000 108.902 0.000
202006 0.003 108.767 0.004
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.010 111.754 0.012
202106 0.009 114.631 0.010
202109 0.009 115.734 0.010
202112 0.009 117.630 0.010
202203 0.009 121.301 0.010
202206 0.009 125.017 0.009
202209 0.009 125.227 0.009
202212 0.006 125.222 0.006
202303 0.006 127.348 0.006
202306 0.006 128.729 0.006
202309 0.006 129.860 0.006
202312 0.006 129.419 0.006
202403 0.006 131.776 0.006

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


SILO Pharma  (NAS:SILO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SILO Pharma was 250.00. The lowest was 22.33. And the median was 91.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


SILO Pharma Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of SILO Pharma's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


SILO Pharma (SILO Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ, USA, 07632
SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is engaged in developing innovative solutions to address a variety of underserved conditions which includes Alzheimer's; Parkinson's; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.
Executives
Eric Weisblum director, officer: President and CCO 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz director 560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman officer: Chief Financial Officer 1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller director
Joel Alan Stone, director 1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps director C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand director, officer: Chairman and CEO 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd 10 percent owner P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats officer: VP of Business Development 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis director, officer: CFO 72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 72 POND ROAD, WOODBURY NY 11797